## Laurence Meyer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/338395/publications.pdf

Version: 2024-02-01

27	1,918	19	27
papers	citations	h-index	g-index
32	32	32	3178
all docs	docs citations	times ranked	citing authors

#	Article	lF	Citations
1	HIV Controllers: A Homogeneous Group of HIV-1-Infected Patients with Spontaneous Control of Viral Replication. Clinical Infectious Diseases, 2005, 41, 1053-1056.	5.8	355
2	Time From Human Immunodeficiency Virus Seroconversion to Reaching CD4+ Cell Count Thresholds <200, <350, and <500 Cells/mm3: Assessment of Need Following Changes in Treatment Guidelines. Clinical Infectious Diseases, 2011, 53, 817-825.	5.8	180
3	Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study. PLoS ONE, 2008, 3, e3907.	2.5	171
4	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14658-14663.	7.1	154
5	Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection. PLoS ONE, 2012, 7, e46143.	2.5	149
6	Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA. Clinical Infectious Diseases, 2015, 60, 1715-1721.	5.8	125
7	Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission. Journal of Antimicrobial Chemotherapy, 2015, 70, 2108-2120.	3.0	92
8	Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients. Aids, 2014, 28, 467-476.	2.2	85
9	Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection. Nature Metabolism, 2019, 1, 704-716.	11.9	72
10	Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. Lancet Infectious Diseases, The, 2015, 15, 387-396.	9.1	67
11	Easy and accurate reconstruction of whole HIV genomes from short-read sequence data with shiver. Virus Evolution, 2018, 4, vey007.	4.9	64
12	Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. PLoS Pathogens, 2016, 12, e1005774.	4.7	50
13	High Soluble CD14 Levels at Primary HIV-1 Infection Predict More Rapid Disease Progression. Journal of Infectious Diseases, 2015, 212, 909-913.	4.0	46
14	When lockdown policies amplify social inequalities in COVID-19 infections: evidence from a cross-sectional population-based survey in France. BMC Public Health, 2021, 21, 705.	2.9	44
15	A highly virulent variant of HIV-1 circulating in the Netherlands. Science, 2022, 375, 540-545.	12.6	39
16	Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. PLoS Biology, 2017, 15, e2001855.	5.6	38
17	TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women. JCI Insight, 2020, 5, .	5.0	36
18	Evaluating Continuity During Transfer to Adult Care: A Systematic Review. Pediatrics, 2016, 138, .	2.1	34

#	Article	IF	CITATIONS
19	Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases, 2018, 66, 1519-1527.	5.8	25
20	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clinical Infectious Diseases, 2021, 73, 50-59.	5.8	18
21	Reprogramming dysfunctional CD8+ T cells to promote properties associated with natural HIV control. Journal of Clinical Investigation, 2022, 132, .	8.2	15
22	Factors associated with failure to return for HIV test results in a free and anonymous screening centre. International Journal of STD and AIDS, 2015, 26, 549-555.	1.1	12
23	Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIVâ€1 infection: results from a longitudinal study in the French ANRS Primo cohort. Journal of the International AIDS Society, 2020, 23, e25485.	3.0	10
24	Ultrasensitive Detection of p24 in Plasma Samples from People with Primary and Chronic HIV-1 Infection. Journal of Virology, 2021, 95, e0001621.	3.4	9
25	Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 2675-2680.	3.0	6
26	Increasing Frequency of Self-Reported Orogenital HIV-1 Transmission Among Men Having Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e164-e166.	2.1	2
27	CXCR3 and CXCR5 are highly expressed in HIVâ€1â€specific CD8 central memory TÂcells from infected patients. European Journal of Immunology, 2021, 51, 2040-2050.	2.9	2